ClinicalTrials.gg
Active, not recruitingNCT07938658QL1706+AG+SBRTUpdated Nov 16, 2026

Iparomlimab and Tuvonralimab Injection (QL1706)Combined With Chemotherapy (AG) and SBRT as First-Line Treatment for Locally Advanced Pancreatic Cancer

A Phase 2 interventional study of Iparomlimab and Tuvonralimab Injection (QL1706) in Pancreatic Ductal Adenocarcinoma (PDAC) and Locally Advanced Pancreatic Cancer, sponsored by Tongji Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Tongji Hospital · Phase 2, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 630 studies in Pancreatic Neoplasms with a site in China — 334 open to participants now, 360 under way, 30 of them phase 3. Pancreatic Neoplasms · China.

Planned enrollment
334th of 508
37 · median 58
Started
2026
with 57 others
Phase 2
155 of 630
89 open now
Primary completion
2028-12
later than 323 of 359 live
Registered
625th of 630
by date

Among the 630 studies in Pancreatic Neoplasms with a site in China, this one is the 334th largest by planned enrollment of the 508 interventional ones that give a count, is one of 58 that started in 2026, is one of 155 in phase 2, reaches primary completion later than 323 of the 359 other live ones, and was the 625th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

334 of the 630 studies in Pancreatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

329 more — sign in →

All 334 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 630 studies in Pancreatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the study drug QL1706 (iparomlimab and tuvonralimab injection) works to treat locally advanced pancreatic cancer in adults when it is given together with chemotherapy and Stereotactic radiotherapy. It will also learn about the safety of this combination treatment.

Around 37 adults aged 18 to 75 who have pancreatic cancer that has grown into nearby tissue and cannot be removed by surgery, but has not spread to other parts of the body, and who have not yet received any treatment for it, will take part in this study.

The main questions it aims to answer are:

Does the combination of QL1706, chemotherapy and radiation make the tumor shrink or stop growing, making it suitable for surgery? How long do participants live without their cancer getting worse, and how long do they live overall? What medical problems do participants have when taking this combination treatment? All participants in this study will receive the same treatment. There is no placebo (a look-alike substance that contains no drug) and no comparison group. Researchers will compare the results of participants in this study with the results usually seen in people who receive chemotherapy alone, to see if adding QL1706 and radiation helps.

Participants will:

Receive QL1706 through a vein (by intravenous infusion) once every 3 weeks Receive 2 chemotherapy drugs through a vein on days 1 and 8 of every 3-week cycle, for 2 cycles. The 2 drugs are gemcitabine and nab-paclitaxel Then receive 5 doses of focused radiation therapy to the pancreas, given about every other day over about 2 weeks, together with 2 more cycles of QL1706 and chemotherapy. Participants whose cancer gets worse during treatment will stop this part of the study Have CT or MRI scans every 6 weeks so the researchers can see whether the cancer has shrunk Have blood tests, physical examinations and other checkups during treatment Be reviewed by a team of pancreatic cancer specialists to see if surgery to remove the tumor is possible. Participants who can have surgery will have the surgery and then 2 to 4 more cycles of QL1706 and chemotherapy. Participants who cannot have surgery, and whose cancer has not grown, will keep receiving QL1706 and chemotherapy until their cancer gets worse, the treatment becomes too hard to tolerate, or they are no longer able to take part Tell the study team about any medical problems they have, which will be recorded throughout the study.

03

Conditions studied

  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Locally Advanced Pancreatic Cancer

Keywords

  • Iparomlimab and Tuvonralimab
  • QL1706
  • Iparomlimab
  • Tuvonralimab
  • Gemcitabine
  • Nab-paclitaxel
  • Stereotactic Body Radiotherapy
  • SBRT
  • Immunotherapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged between 18 and 75 years old, with no gender restriction;
  2. Have been fully informed of this study and voluntarily signed the form.
  3. Patients with histopathologically confirmed pancreatic ductal adenocarcinoma (PDAC) with locally advanced lesions, meeting any of the following criteria and having no distant :

    ① Tumors located in the pancreatic head and neck:

    1. Tumor encasement of the superior mesenteric artery (SMA) exceeding 180°;
    2. Tumor encasement of the celiac trunk exceeding 180°;
    3. Tumor invasion or embolization (tumor thrombus or blood thrombus) rendering the superior mesenteric vein or portal vein unresectable for reconstruction;
    4. Extensive tumor involvement of the distal jejunal draining branch of the superior mesenteric vein.

      • Tumors located in the pancreatic body/tail:

    <!-- -->

    1. Tumor encasement of the superior mesenteric artery or celiac trunk exceeding 180°;
    2. Involvement of the celiac trunk and abdominal aorta;
    3. Tumor invasion or embolization (tumor thrombus or blood thrombus) making resection and reconstruction of the superior mesenteric vein or portal vein impossible.
  4. Good physical status: (ECOG) performance status score of 0-1;
  5. Willing and able to comply with medical advice and receive combination therapy with gemcitabine for injection and paclitaxel (albumin-bound) for injection;
  6. No dysfunction of major organs, and laboratory test results meet the basic requirements for chemotherapy, as follows:

    1. ≥ 1.5×10⁹/L;
    2. count ≥ 90×10⁹/L;
    3. (Hb) ≥ 90 g/L;
    4. Serum (AST) and alanine aminotransferase (ALT) ≤ 1.5 times the (ULN); for patients with liver metastasis, AST and ALT ≤ 5.0 times ULN;
    5. Total ≤ 1.5 times ULN;
    6. Serum creatinine ≤ 1.5 times ULN;
    7. Q-T interval on ≤ 450 ms;
    8. Normal serum electrolytes (sodium, potassium, chloride and total calcium).
  7. Women of must agree to use measures throughout the study period and for 3 months after study completion; they must have a negative serum or urine pregnancy test within 7 days prior to enrollment and must not be breastfeeding. Male participants must agree to use contraceptive measures during the study and for 3 months after the end of the study.
  8. No other to treatment prior to enrollment. The patient voluntarily participates in the trial, has good treatment compliance, and can cooperate with trial observations.

Exclusion criteria

Exclusion Criteria:

  1. Patients with acinic cell carcinoma, pancreatoblastoma, solid pseudopapillary neoplasm, or pancreatic neuroendocrine neoplasm;
  2. Subjects who have previously received treatment for pancreatic adenocarcinoma;
  3. Subjects with to treatment with gemcitabine for injection and/or albumin-bound paclitaxel for injection, or with known severe to gemcitabine for injection and/or albumin-bound paclitaxel for injection;
  4. Pregnant or lactating women; women of with a positive baseline pregnancy test;
  5. History of other malignant tumors within the past 5 years (excluding basal cell carcinoma, squamous cell carcinoma, superficial bladder cancer, carcinoma in situ of the cervix, and breast cancer);
  6. Uncontrolled pleural effusion, pericardial effusion, or ascites;
  7. Severe cardiovascular diseases occurring within 12 months prior to admission, including symptomatic coronary heart disease, grade ≥ II congestive heart failure, uncontrolled arrhythmia, or myocardial infarction;
  8. Complicated gastroduodenal obstruction/hemorrhage, digestive dysfunction, or malabsorption syndrome;
  9. Presence of severe uncontrolled concurrent infection, other severe uncontrolled comorbidities, or moderate to severe renal impairment;
  10. History of allergic reactions to the study medications used in this trial;
  11. Use of or other systemic therapies within 14 days prior to admission;
  12. Subjects who received drug treatment within 4 weeks before enrollment (participation in other clinical trials);
  13. Active diseases (including but not limited to uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, hypothyroidism, and asthma requiring bronchodilator therapy). Exceptions may be made for patients with hypothyroidism managed solely with hormone replacement therapy and patients with skin diseases not requiring systemic treatment (such as vitiligo, psoriasis, or alopecia);
  14. Medical history of primary immunodeficiency;
  15. Use of immunosuppressive drugs within 4 weeks before the first dose of study treatment, excluding topical or physiologic doses of systemic corticosteroids (i.e., prednisone ≤ 10 mg/day or equivalent doses of other corticosteroids) administered via nasal spray, inhalation or other routes, or corticosteroids used for the prevention of contrast medium allergy;
  16. Receipt of within 4 weeks before the first dose of study treatment or during the study period;
  17. Known active pulmonary tuberculosis;
  18. History of allogeneic organ transplantation or hematopoietic stem cell transplantation;
  19. Positive antibody, or active or infection (Hepatitis B: positive HBsAg with HBV DNA ≥ 10⁴ copies/mL; Hepatitis C: positive HCV antibody and HCV-RNA requiring antiviral treatment);
  20. Other factors that, in the investigator's opinion, may compromise subject safety or trial compliance, such as severe diseases requiring comprehensive treatment (including psychiatric disorders), significant laboratory abnormalities, or other familial and social factors.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (estimated)

Study arms

  • Experimental
    QL1706 combined with AG and SBRT

    Receive QL1706 through a vein (by intravenous infusion) once every 3 weeks Receive 2 chemotherapy drugs through a vein on days 1 and 8 of every 3-week cycle, for 2 cycles. The 2 drugs are gemcitabine and nab-paclitaxel Then receive SBRT to the pancreatic cancer, given about every other day over about 2 weeks, together with 2 more cycles of QL1706 and chemotherapy.

    Drug: Iparomlimab and Tuvonralimab Injection (QL1706)

Interventions

  • DrugIparomlimab and Tuvonralimab Injection (QL1706)

    Drug page: Iparomlimab/Tuvonralimab

    combination of QL1706, AG chemotherapy and Stereotactic radiotherapy

    Also known as: Stereotactic radiotherapy, gemcitabine and nab-paclitaxel

06

What researchers measure

Primary outcomes

  1. ORR

    Objective Response Rate

    Time frame: From enrollment to the end of combination treatment at 8 weeks

Secondary outcomes

  1. PFS

    Progression-Free Survival

    Time frame: From date of randomization until the date of first documented disease progression (per RECIST v1.1 ) or date of death from any cause, whichever came first, assessed up to 30 months.

  2. OS

    Overall Survival

    Time frame: From date of randomization until the date of death from any cause, assessed up to 60 months

  3. AE

    Adverse Events

    Time frame: From the date of first study intervention administration through the end of the 8-week treatment period and up to 30 days after the last dose.

07

Study locations

1 site
08

References and documents

Publications

  • Mansour AM, Yahia S, Elsayed HRH, El-Attar SAE, Grawish ME, El-Hawary YM, El-Sherbiny IM. Efficacy of biocompatible trilayers nanofibrous scaffold with/without allogeneic adipose-derived stem cells on class II furcation defects of dogs' model. Clin Oral Investig. 2022 Mar;26(3):2537-2553. doi: 10.1007/s00784-021-04222-x. Epub 2021 Oct 18. PubMed 34661742 ↗
  • Shibli Abu Raya Y, Bilgory A, Aslih N, Atzmon Y, Shavit M, Estrada D, Sharqawi M, Shalom-Paz E. High initial beta-hCG predicts IVF outcomes accurately and precludes the need for repeated measurements. Endocr Connect. 2023 Sep 27;12(11):e230189. doi: 10.1530/EC-23-0189. Print 2023 Nov 1. PubMed 37555512 ↗

Individual participant data

Plan to share: Yes — The de-identified individual participant data that underlie the results reported in this study, together with the study protocol and statistical analysis plan, will be available from the corresponding author upon reasonable request after publication of the primary results. Data will be shared for non-commercial academic research purposes only, and requestors will be required to sign a data transfer agreement. The data will be provided in a de-identified form in accordance with the informed consent obtained from participants and applicable regulations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 6 months and ending 36 months after publication of the primary results.

Access criteria: Qualified researchers with an approved methodologically sound proposal and a signed data access agreement.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2028, 27 months after the start.

Of 324 non-industry phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 80. This study's planned 27 months is below that.

Counting every sponsor, half of 393 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2026
First posted
Nov 16, 2026
StartActual
Sep 14, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938658
Lead sponsor
Tongji Hospital
Responsible party
Qiang Fu (Associate Professor & Associate Chief Physician, Tongji Hospital) — Principal investigator
First posted
Nov 16, 2026
Start date
Sep 14, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iparomlimab/Tuvonralimab

Start the discussion